Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioning

Experimental Hematology

Volumn 40, Issue 2, 2012, Pages 97-106

  Schwaiger, Elisabeth ^a   Klaus, Christoph ^a   Matheeussen, Veerle ^b   Baranyi, Ulrike ^a   Pilat, Nina ^a   Ramsey, Haley ^a   Korom, Stephan ^c   De Meester, Ingrid ^b   Wekerle, Thomas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPROTIN A; SITAGLIPTIN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENGRAFTMENT; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; FEMALE; GRAFT REJECTION; IN VITRO STUDY; IN VIVO STUDY; ISOGRAFT; MOUSE; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; WHOLE BODY RADIATION;

ANIMALS; BONE MARROW TRANSPLANTATION; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; OLIGOPEPTIDES; PYRAZINES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TRIAZOLES;

MURINAE;

EID: 84855610542     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.10.010     Document Type: Article

References (47)

1. Pilat N., Wekerle T. Transplantation tolerance through mixed chimerism. Nat Rev Nephrol 2010, 6:594-605.
2. Kawai T., Cosimi A.B., Spitzer T.R., et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008, 358:353-361.
3. Fehr T., Sykes M. Clinical experience with mixed chimerism to induce transplantation tolerance. Transpl Int 2008, 21:1118-1135.
4. Pilat N., Klaus C., Schwaiger E., Wekerle T. Hurdles to the induction of tolerogenic mixed chimerism. Transplantation 2009, 87(Suppl):S79-S84.
5. Vincenti F., Larsen C., Durrbach A., et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005, 353:770-781.
6. Pree I., Wekerle T. New approaches to prevent transplant rejection: costimulation blockers anti-CD40L and CTLA4Ig. Drug Discov Today Ther Strateg 2006, 3:41-47.
7. Wekerle T., Sayegh M.H., Hill J., et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 1998, 187:2037-2044.
8. Wekerle T., Kurtz J., Ito H., et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000, 6:464-469.
9. Adams A.B., Durham M.M., Kean L., et al. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol 2001, 167:1103-1111.
10. Lambert J.F., Colvin G.A., Zhong S., et al. H2-mismatched transplantation with repetitive cell infusions and CD40 ligand antibody infusions without myeloablation. Br J Haematol 2002, 119:155-163.
11. Wekerle T., Blaha P., Langer F., Schmid M., Muehlbacher F. Tolerance through bone marrow transplantation with costimulation blockade. Transpl Immunol 2002, 9:125-133.
12. Blaha P., Bigenzahn S., Koporc Z., et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 2003, 101:2886-2893.
13. Taylor P.A., Lees C.J., Wilson J.M., et al. Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions. Blood 2002, 100:3400-3407.
14. Pilat N., Baranyi U., Klaus C., et al. Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioning. Am J Transplant 2010, 10:751-762.
15. Kean L.S., Adams A.B., Strobert E., et al. Induction of chimerism in rhesus macaques through stem cell transplant and costimulation blockade-based immunosuppression. Am J Transplant 2007, 7:320-335.
16. Kawai T., Sogawa H., Boskovic S., et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant 2004, 4:1391-1398.
17. Peled A., Petit I., Kollet O., et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999, 283:845-848.
18. Lambeir A.M., Proost P., Durinx C., et al. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem 2001, 276:29839-29845.
19. Christopherson K.W., Hangoc G., Broxmeyer H.E. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol 2002, 169:7000-7008.
20. Christopherson K.W., Hangoc G., Mantel C.R., Broxmeyer H.E. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004, 305:1000-1003.
21. Tian C., Bagley J., Forman D., Iacomini J. Inhibition of CD26 peptidase activity significantly improves engraftment of retrovirally transduced hematopoietic progenitors. Gene Ther 2006, 13:652-658.
22. Peranteau W.H., Endo M., Adibe O.O., Merchant A., Zoltick P.W., Flake A.W. CD26 inhibition enhances allogeneic donor-cell homing and engraftment after in utero hematopoietic-cell transplantation. Blood 2006, 108:4268-4274.
23. Christopherson K.W., Paganessi L.A., Napier S., Porecha N.K. CD26 inhibition on CD34+ or lineage-human umbilical cord blood donor hematopoietic stem cells/hematopoietic progenitor cells improves long-term engraftment into NOD/SCID/Beta2null immunodeficient mice. Stem Cells Dev 2007, 16:355-360.
24. Kawai T., Choi U., Liu P.C., Whiting-Theobald N.L., Linton G.F., Malech H.L. Diprotin A infusion into nonobese diabetic/severe combined immunodeficiency mice markedly enhances engraftment of human mobilized CD34+ peripheral blood cells. Stem Cells Dev 2007, 16:361-370.
25. Campbell T.B., Hangoc G., Liu Y., Pollok K., Broxmeyer H.E. Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells Dev 2007, 16:347-354.
26. Korom S., De Meester I., Stadlbauer T.H., et al. Inhibition of CD26/dipeptidyl peptidase IV activity invivo prolongs cardiac allograft survival in rat recipients. Transplantation 1997, 63:1495-1500.
27. Jung F.J., Yang L., De Meester I., et al. CD26/dipeptidylpeptidase IV-targeted therapy of acute lung rejection in rats. J Heart Lung Transplant 2006, 25:1109-1116.
28. Zhai W., Cardell M., De Meester I., et al. Ischemia/reperfusion injury: the role of CD26/dipeptidyl-peptidase-IV-inhibition in lung transplantation. Transplant Proc 2006, 38:3369-3371.
29. Lambeir A.M., Durinx C., Scharpe S., De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003, 40:209-294.
30. Gorrell M.D. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond) 2005, 108:277-292.
31. Tanaka T., Kameoka J., Yaron A., Schlossman S.F., Morimoto C. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc Natl Acad Sci U S A 1993, 90:4586-4590.
32. Tanaka T. Cloning and functional expression of the T cell activation antigen CD26. J Immunol 1993, 150:2090.
33. Liu Z., Christensson M., Forslow A., De Meester I., Sundqvist K.G. A CD26-controlled cell surface cascade for regulation of T cell motility and chemokine signals. J Immunol 2009, 183:3616-3624.
34. Ohnuma K., Dang N.H., Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol 2008, 29:295-301.
35. Ahren B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab 2007, 21:517-533.
36. Koporc Z., Bigenzahn S., Blaha P., et al. Induction of mixed chimerism through transplantation of CD45-congenic mobilized peripheral blood stem cells after nonmyeloablative irradiation. Biol Blood Marrow Transplant 2006, 12:284-292.
37. Christopherson K.W., Cooper S., Broxmeyer H.E. Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood 2003, 101:4680-4686.
38. Broxmeyer H.E., Hangoc G., Cooper S., Campbell T., Ito S., Mantel C. AMD3100 and CD26 modulate mobilization, engraftment, and survival of hematopoietic stem and progenitor cells mediated bytheSDF-1/CXCL12-CXCR4 axis. Ann N Y Acad Sci 2007, 1106:1-19.
39. Matheeussen V., Baerts L., De Meyer G., et al. Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol Chem 2011, 392:189-198.
40. Scharpe S., De Meester I., Vanhoof G., et al. Assay of dipeptidyl peptidase IV in serum by fluorometry of 4-methoxy-2-naphthylamine. Clin Chem 1988, 34:2299-2301.
41. Ito H., Takeuchi Y., Shaffer J., Sykes M. Local irradiation enhances congenic donor pluripotent hematopoietic stem cell engraftment similarly in irradiated and nonirradiated sites. Blood 2004, 103:1949-1954.
42. Charbonnel B., Karasik A., Liu J., Wu M., Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006, 29:2638-2643.
43. Miller S., St Onge E.L. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother 2006, 40:1336-1343.
44. Markees T.G., Phillips N.E., Gordon E.J., et al. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. J Clin Invest 1998, 101:2446-2455.
45. Pilat N., Klaus C., Gattringer M., et al. Therapeutic efficacy of polyclonal Tregs does not require rapamycin in a low-dose irradiation bone marrow transplantation model. Transplantation 2011, 92:280-288.
46. Lankas G.R., Leiting B., Roy R.S., et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005, 54:2988-2994.
47. Kim S.J., Nian C., Doudet D.J., McIntosh C.H. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes 2008, 57:1331-1339.